Review Article
John Murphy, CEO, COVID-19 Long haul Foundation
Abstract
Coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), is increasingly recognized as a multisystem vascular disease in addition to a respiratory infection. Since 2020, accumulating evidence has demonstrated that endothelial injury, platelet activation, dysregulated coagulation, immune activation, and persistent inflammatory responses contribute to widespread microvascular pathology. Among the most compelling findings has been the identification of fibrin-rich amyloid microclots that appear resistant to physiological fibrinolysis and may impair tissue perfusion in multiple organs, including the brain.
Neurological manifestations occur in approximately one-third of hospitalized patients during acute infection and remain among the most disabling features of post-acute sequelae of SARS-CoV-2 infection (PASC), commonly known as Long COVID. Cognitive dysfunction (“brain fog”), executive impairment, memory loss, fatigue, autonomic dysfunction, headache, dysautonomia, sleep disorders, depression, anxiety, anosmia, and cerebrovascular complications collectively affect millions worldwide.
Emerging evidence suggests that cerebral microvascular dysfunction may represent a unifying mechanism linking persistent endothelial inflammation, blood-brain barrier disruption, platelet hyperactivation, complement activation, and neuroinflammation. Microclots may impair oxygen and nutrient delivery while promoting chronic hypoperfusion, mitochondrial dysfunction, and activation of resident microglia. These processes appear capable of producing diffuse neuronal dysfunction even in the absence of large-vessel stroke.
This review summarizes current understanding of SARS-CoV-2-associated cerebral microclot formation, integrating advances in vascular biology, neuropathology, immunology, neuroimaging, and clinical neurology. Diagnostic approaches, therapeutic strategies, unresolved controversies, and future research priorities are discussed.
Introduction
The COVID-19 pandemic fundamentally altered understanding of viral diseases affecting the nervous system. Initially characterized as an atypical viral pneumonia, SARS-CoV-2 rapidly demonstrated an extraordinary capacity to involve virtually every organ system. Among its most intriguing and clinically significant manifestations are persistent neurological symptoms that continue months or years after acute infection.
Unlike many respiratory viruses, SARS-CoV-2 exerts profound effects on vascular homeostasis. Autopsy studies early in the pandemic revealed diffuse endothelial inflammation, capillary injury, platelet-rich thrombi, complement deposition, and extensive microvascular abnormalities throughout multiple organ systems. These observations shifted scientific attention toward vascular mechanisms as potential drivers of persistent disease.
The brain is uniquely vulnerable to disturbances in microvascular circulation. Although it comprises only approximately 2% of total body weight, it consumes roughly 20% of resting oxygen delivery. Neurons possess limited energy reserves and are exquisitely sensitive to even brief reductions in oxygen or glucose availability. Consequently, diffuse impairment of cerebral capillary perfusion—even without overt ischemic stroke—may produce measurable deficits in cognition, attention, executive function, and memory.
Long COVID has emerged as one of the defining chronic illnesses of the twenty-first century. Estimates vary depending on diagnostic criteria and study population, but persistent symptoms extending beyond three months affect a substantial minority of infected individuals. Neurological complaints consistently rank among the most prevalent and disabling manifestations.
One proposed mechanism centers on persistent fibrin amyloid microclots. Laboratory investigations have demonstrated abnormal fibrin polymerization resistant to fibrinolysis in some patients with Long COVID. These microclots may entrap inflammatory mediators, impair capillary blood flow, activate endothelial cells, and perpetuate inflammatory signaling. Although the precise contribution of these findings to clinical disease remains an area of active investigation, they represent one of several plausible mechanisms for ongoing neurological dysfunction.
Importantly, microclots should not be viewed in isolation. Current evidence supports a multifactorial model in which endothelial injury, immune dysregulation, platelet activation, persistent inflammation, autonomic dysfunction, mitochondrial impairment, and microvascular abnormalities likely interact to produce the heterogeneous clinical syndrome recognized as Long COVID.
Virology of SARS-CoV-2
SARS-CoV-2 belongs to the family Coronaviridae and contains a positive-sense single-stranded RNA genome approximately 30 kilobases in length. Viral entry depends primarily upon binding of the spike glycoprotein to angiotensin-converting enzyme 2 (ACE2), followed by proteolytic activation by host enzymes including TMPRSS2.
ACE2 expression extends far beyond pulmonary tissue and includes:
- vascular endothelial cells
- pericytes
- cardiac tissue
- renal tubular epithelium
- intestinal mucosa
- olfactory epithelium
- selected neural tissues
The broad distribution of ACE2 partially explains the systemic manifestations of COVID-19. Infection initiates innate immune activation through recognition of viral RNA by pattern recognition receptors, leading to production of interferons, cytokines, and chemokines. While protective in many individuals, dysregulated immune responses may promote widespread endothelial activation and coagulation abnormalities.
Cerebral Vascular Anatomy and Physiological Vulnerability
Normal cerebral function depends upon uninterrupted perfusion through an extraordinarily dense capillary network. Approximately 600 kilometers of cerebral capillaries continuously supply oxygen and glucose to neurons. Neurovascular coupling precisely regulates regional blood flow according to metabolic demand.
Endothelial cells, astrocytes, pericytes, and neurons together comprise the neurovascular unit. Disruption of any component may impair neuronal homeostasis.
Pericytes deserve particular attention because they regulate capillary diameter, blood-brain barrier integrity, and cerebral perfusion. Experimental evidence suggests SARS-CoV-2-related inflammatory responses may impair pericyte function, contributing to microvascular dysregulation.
The blood-brain barrier further protects neural tissue through tightly regulated endothelial junctions. Inflammatory cytokines, complement activation, oxidative stress, and endothelial injury may compromise this barrier, allowing circulating inflammatory mediators greater access to the central nervous system.
Etiology of COVID-Associated Brain Microclots
Several interacting mechanisms likely contribute to cerebral microclot formation.
Endothelial Injury
Healthy vascular endothelium maintains an anticoagulant surface through production of nitric oxide, prostacyclin, thrombomodulin, and tissue plasminogen activator.
SARS-CoV-2 infection disrupts this equilibrium through:
- endothelial activation
- oxidative stress
- inflammatory cytokines
- complement activation
- leukocyte adhesion
- reduced nitric oxide bioavailability
Activated endothelial cells increasingly express tissue factor and von Willebrand factor, promoting platelet adhesion and thrombus formation.
Platelet Hyperactivation
Multiple investigations demonstrate abnormal platelet activation during acute COVID-19. Activated platelets exhibit:
- increased aggregation
- excessive thromboxane production
- release of procoagulant microparticles
- enhanced interaction with neutrophils
- increased P-selectin expression
Platelet-neutrophil interactions further amplify thrombosis through formation of neutrophil extracellular traps (NETs), which provide structural scaffolding for fibrin deposition.
Hypercoagulability
COVID-19 induces one of the most complex coagulopathies described in infectious diseases.
Characteristic laboratory abnormalities include:
- elevated D-dimer
- increased fibrinogen
- elevated factor VIII
- increased von Willebrand factor
- impaired fibrinolysis
- thrombin generation
Unlike disseminated intravascular coagulation, COVID-associated coagulopathy often demonstrates preserved platelet counts during early disease while maintaining marked thrombotic potential.
Molecular Mechanisms of Cerebral Microclot Formation and Their Contribution to Neurological Dysfunction
Fibrin Amyloid Microclots
Perhaps the most provocative observation in Long COVID research has been the description of persistent fibrin(ogen)-rich microclots exhibiting amyloid-like properties and resistance to physiological fibrinolysis. Investigators have proposed that these structures may contribute to impaired microvascular perfusion, although their prevalence, clinical significance, and causal role remain areas of active research rather than established clinical fact.
Under normal conditions, fibrinogen is converted by thrombin into fibrin monomers, which polymerize to form a temporary hemostatic mesh. Tissue plasminogen activator (tPA) subsequently converts plasminogen to plasmin, leading to fibrin degradation and restoration of normal vascular patency.
During acute SARS-CoV-2 infection, multiple perturbations alter this tightly regulated system:
- marked thrombin generation;
- elevated fibrinogen concentrations;
- increased Factor VIII activity;
- endothelial activation;
- platelet hyper-reactivity;
- complement activation;
- inflammatory cytokine release.
The resulting fibrin network may become unusually dense and extensively cross-linked through activated Factor XIII. Simultaneously, fibrinolysis appears impaired by elevated concentrations of plasminogen activator inhibitor-1 (PAI-1), reducing the capacity for physiological clot dissolution.
Some investigators have reported that these fibrin structures bind amyloid-sensitive fluorescent dyes, suggesting abnormal protein folding reminiscent of amyloidogenesis. Whether these amyloid characteristics are unique to COVID-19 or occur in other inflammatory disorders remains incompletely resolved.
Entrapment of Inflammatory Mediators
One particularly intriguing hypothesis proposes that persistent fibrin microclots function as biological reservoirs that sequester inflammatory proteins.
Proteomic analyses have demonstrated enrichment of several molecules within isolated microclots, including:
- α2-antiplasmin
- fibrinogen
- serum amyloid A
- complement proteins
- von Willebrand factor
- fibronectin
- inflammatory cytokines
Entrapment of α2-antiplasmin is especially noteworthy because it inhibits plasmin activity, potentially rendering fibrin deposits unusually resistant to degradation.
This phenomenon may establish a self-perpetuating cycle:
Endothelial injury →
Platelet activation →
Fibrin deposition →
Inflammatory protein sequestration →
Impaired fibrinolysis →
Persistent endothelial activation
Although compelling, this model requires further validation in large prospective cohorts.
Endotheliopathy
Accumulating evidence suggests that endothelial dysfunction represents one of the central pathophysiological processes underlying severe COVID-19.
Healthy endothelium maintains vascular homeostasis through numerous mechanisms:
- nitric oxide production
- prostacyclin synthesis
- regulation of vascular tone
- inhibition of platelet adhesion
- anticoagulant surface proteins
- regulation of leukocyte trafficking
SARS-CoV-2 profoundly disrupts these protective mechanisms.
Activated endothelial cells exhibit increased expression of:
- ICAM-1
- VCAM-1
- E-selectin
- P-selectin
- tissue factor
These adhesion molecules facilitate recruitment of neutrophils, monocytes, and activated lymphocytes to the vascular wall, amplifying local inflammation.
Loss of endothelial nitric oxide synthase activity reduces nitric oxide production, promoting vasoconstriction, platelet aggregation, oxidative stress, and impaired cerebral autoregulation.
Blood–Brain Barrier Dysfunction
The blood–brain barrier (BBB) consists primarily of specialized endothelial cells joined by tight junction proteins including claudins, occludins, and zonula occludens proteins.
This barrier regulates:
- nutrient transport
- immune surveillance
- toxin exclusion
- maintenance of cerebral homeostasis
Inflammatory mediators released during COVID-19—including IL-6, TNF-α, IL-1β, interferon-γ, and complement components—may alter endothelial permeability.
Experimental studies demonstrate:
- reduced tight junction integrity;
- increased endothelial permeability;
- astrocyte activation;
- basement membrane injury;
- leukocyte migration into perivascular tissues.
Even subtle disruption of BBB integrity may expose neurons to circulating cytokines, coagulation proteins, and immune mediators normally excluded from the central nervous system.
Such alterations may contribute to persistent neuroinflammation despite clearance of replicating virus.
Cerebral Hypoperfusion
Unlike large-vessel stroke, cerebral microvascular dysfunction often produces diffuse rather than focal neurological deficits.
Microvascular obstruction may reduce oxygen extraction across thousands of capillaries simultaneously.
Neurons possess exceptionally high metabolic demand.
Although constituting only approximately two percent of body mass, the adult human brain consumes roughly:
- 20% of resting oxygen
- 25% of total glucose
- approximately 20% of cardiac output
Even modest reductions in capillary perfusion may impair:
- ATP synthesis
- neurotransmitter recycling
- axonal transport
- synaptic transmission
- ion pump activity
Patients therefore may experience cognitive slowing without evidence of infarction on conventional neuroimaging.
This mechanism has been proposed as one explanation for the characteristic “brain fog” reported in Long COVID.
Neurovascular Unit Dysfunction
Modern neuroscience increasingly recognizes the neurovascular unit rather than the neuron alone as the fundamental functional element of cerebral physiology.
The neurovascular unit comprises:
- endothelial cells
- pericytes
- astrocytes
- neurons
- microglia
- extracellular matrix
Normal cognition depends upon coordinated interaction among these cellular components.
Pericytes regulate capillary diameter in response to neuronal activity.
Astrocytes couple synaptic metabolism to vascular perfusion.
Microglia provide immune surveillance while pruning dysfunctional synapses.
Endothelial cells regulate nutrient delivery.
Disruption of any component may impair cognition.
Persistent endothelial inflammation may therefore produce widespread disturbances in neurovascular coupling despite structurally intact neurons.
Microglial Activation
Microglia represent the resident macrophages of the central nervous system.
During physiological conditions they maintain tissue homeostasis by:
- removing apoptotic cells
- remodeling synapses
- supporting neuronal survival
- responding to injury
Inflammatory cytokines crossing a compromised BBB activate microglia.
Activated microglia release:
- IL-1β
- IL-6
- TNF-α
- reactive oxygen species
- nitric oxide
- glutamate
Persistent activation may produce chronic neuroinflammation.
Importantly, neuroinflammation does not necessarily imply neuronal death.
Instead, prolonged cytokine exposure may alter neuronal signaling sufficiently to impair cognition while remaining potentially reversible.
Astrocyte Dysfunction
Astrocytes regulate:
- glutamate recycling
- potassium buffering
- cerebral blood flow
- BBB maintenance
- metabolic support of neurons
Reactive astrocytes demonstrate:
- hypertrophy
- altered gene expression
- inflammatory mediator release
- impaired neurotransmitter recycling
Failure to efficiently remove extracellular glutamate may contribute to excitotoxic stress.
Reduced astrocytic lactate delivery may further impair neuronal metabolism.
Mitochondrial Dysfunction
Energy failure has emerged as another prominent hypothesis explaining persistent neurological symptoms.
Neurons contain thousands of mitochondria because of extraordinary ATP requirements.
Several mechanisms may converge to impair mitochondrial function:
Hypoxia
Reduced microvascular perfusion decreases oxygen availability.
Inflammation
Cytokines interfere with oxidative phosphorylation.
Reactive oxygen species
Oxidative injury damages mitochondrial DNA.
Calcium dysregulation
Inflammation disrupts intracellular calcium homeostasis.
Nitric oxide imbalance
Excess nitric oxide inhibits electron transport chain complexes.
The cumulative result is reduced ATP generation.
Clinically, patients may experience:
- mental fatigue
- slowed information processing
- impaired concentration
- reduced cognitive endurance
- post-exertional symptom exacerbation
Oxidative Stress
Inflammation increases production of reactive oxygen species by:
- activated neutrophils
- macrophages
- dysfunctional mitochondria
- endothelial NADPH oxidase
Oxidative stress damages:
- lipids
- proteins
- DNA
- mitochondrial membranes
- endothelial glycocalyx
The glycocalyx—a carbohydrate-rich protective endothelial surface—is increasingly recognized as essential for vascular integrity.
Damage to this structure promotes:
- platelet adhesion
- leukocyte recruitment
- increased vascular permeability
- impaired nitric oxide signaling
Complement Activation
Complement activation represents another important contributor to COVID-associated vascular pathology.
Autopsy investigations have demonstrated deposition of:
- C3
- C4d
- C5b-9 membrane attack complex
within cerebral microvasculature.
Complement activation promotes:
- endothelial injury
- platelet activation
- neutrophil recruitment
- thrombin generation
This creates additional positive feedback loops linking innate immunity with coagulation.
Neutrophil Extracellular Traps (NETs)
Activated neutrophils may extrude extracellular DNA decorated with histones and antimicrobial proteins.
These structures, termed NETs, function to immobilize pathogens but also possess potent prothrombotic properties.
NETs provide a scaffold for:
- platelet adhesion
- fibrin polymerization
- coagulation factor activation
- complement deposition
Excessive NET formation has been documented during acute COVID-19 and may contribute to persistent microvascular abnormalities in susceptible individuals.
Summary
Current evidence supports a multifactorial model in which cerebral dysfunction after COVID-19 arises from interacting mechanisms rather than a single pathological process. Endothelial injury, platelet activation, dysregulated coagulation, fibrin-rich microclots, blood–brain barrier disruption, neuroinflammation, mitochondrial dysfunction, oxidative stress, and impaired neurovascular coupling may together contribute to the neurological manifestations of Long COVID. While these mechanisms are biologically plausible and supported by varying degrees of experimental and clinical evidence, the relative contribution of each pathway likely differs among patients, and several aspects—including the direct clinical significance of persistent circulating microclots—remain under active investigation.
Neuropathology
Neuropathological studies performed since 2020 have fundamentally changed our understanding of neurological injury associated with SARS-CoV-2 infection. Unlike classical viral encephalitides, in which widespread viral invasion of neurons predominates, many autopsy investigations of COVID-19 have demonstrated diffuse microvascular injury, endothelial activation, perivascular inflammation, microglial activation, and occasional microthrombi, while direct viral invasion of neurons appears limited in most cases. This distinction suggests that much of the neurological injury may arise from vascular and inflammatory mechanisms rather than direct viral cytotoxicity.
Several pathological patterns have emerged repeatedly.
Cerebral Microvascular Injury
Microscopic examination frequently reveals:
- endothelial swelling;
- disruption of capillary integrity;
- fibrin deposition;
- platelet-rich microthrombi;
- perivascular inflammatory infiltrates;
- petechial hemorrhages;
- diffuse hypoxic injury.
These lesions are often multifocal and distributed throughout the cerebral cortex, basal ganglia, cerebellum, and brainstem rather than confined to a single vascular territory.
Such diffuse injury is consistent with impairment of cerebral perfusion at the capillary level.
White Matter Injury
One of the most consistent neuropathological findings involves injury to cerebral white matter.
Affected regions may demonstrate:
- axonal swelling;
- myelin pallor;
- activated macrophages;
- reactive astrocytosis;
- microglial nodules.
White matter tracts serve as the communication network linking distributed cortical regions responsible for memory, attention, executive function, and language.
Consequently, diffuse white matter injury may produce global cognitive slowing rather than focal neurological deficits.
This pattern resembles certain forms of vascular cognitive impairment.
Hippocampal Injury
The hippocampus remains particularly susceptible to ischemia because of its exceptionally high metabolic requirements.
Experimental studies suggest several mechanisms capable of affecting hippocampal function:
- impaired capillary perfusion;
- neuroinflammation;
- cytokine-mediated synaptic dysfunction;
- oxidative stress;
- mitochondrial injury.
Clinically, hippocampal dysfunction may contribute to:
- impaired short-term memory;
- reduced learning efficiency;
- difficulty forming new memories;
- impaired spatial navigation.
Many patients with Long COVID describe repeatedly forgetting conversations, appointments, names, and recently acquired information.
Brainstem Pathology
The brainstem contains nuclei responsible for:
- respiratory control;
- cardiovascular regulation;
- autonomic nervous system function;
- vestibular processing;
- cranial nerve function.
Inflammatory injury involving these structures has been proposed as one explanation for persistent:
- dysautonomia;
- orthostatic intolerance;
- chronic dizziness;
- heart-rate variability abnormalities;
- impaired respiratory control.
Because autonomic dysfunction frequently accompanies cognitive impairment, shared vascular mechanisms remain plausible.
Microglial Nodules
Autopsy investigations have repeatedly demonstrated clusters of activated microglia throughout the cerebral cortex and brainstem.
Microglial nodules generally indicate chronic immune activation.
Persistent microglial activation may alter:
- synaptic transmission;
- dendritic remodeling;
- neuronal metabolism;
- neurotransmitter balance.
Importantly, such changes may be potentially reversible if inflammatory signaling subsides.
Neuroimaging
Conventional MRI often appears remarkably normal despite substantial neurological symptoms.
This apparent paradox has prompted increasing utilization of advanced neuroimaging techniques.
Magnetic Resonance Imaging (MRI)
Routine MRI may demonstrate:
- scattered white matter hyperintensities;
- small ischemic lesions;
- microhemorrhages;
- cortical atrophy in severe disease;
- enlarged perivascular spaces.
However, many patients with disabling cognitive dysfunction exhibit entirely normal structural MRI examinations.
This observation suggests that functional abnormalities frequently precede irreversible structural injury.
Susceptibility-Weighted Imaging
Susceptibility-weighted imaging (SWI) has improved detection of cerebral microhemorrhages.
Microhemorrhages may reflect:
- endothelial disruption;
- capillary fragility;
- inflammatory vascular injury;
- microvascular thrombosis.
Their presence correlates more strongly with severe acute illness than with uncomplicated Long COVID.
Diffusion Tensor Imaging
Diffusion tensor imaging (DTI) measures water diffusion along white matter tracts.
Several investigations have demonstrated abnormalities involving:
- corpus callosum;
- superior longitudinal fasciculus;
- frontal association pathways;
- limbic connections.
Reduced fractional anisotropy suggests impaired white matter integrity.
Such abnormalities correlate with reduced processing speed and executive dysfunction.
Functional MRI
Functional MRI evaluates synchronized neuronal activity rather than anatomy.
Long COVID investigations have demonstrated altered connectivity involving:
- default mode network;
- salience network;
- frontoparietal attention network;
- hippocampal circuits.
These findings may explain difficulties involving:
- multitasking;
- sustained attention;
- working memory;
- executive planning.
Positron Emission Tomography
Among neuroimaging techniques, fluorodeoxyglucose positron emission tomography (FDG-PET) has yielded particularly interesting findings.
Multiple studies demonstrate cerebral hypometabolism involving:
- frontal cortex;
- orbitofrontal cortex;
- anterior cingulate cortex;
- temporal lobes;
- cerebellum;
- brainstem.
Reduced glucose metabolism likely reflects diminished neuronal activity rather than neuronal death.
Some longitudinal investigations demonstrate gradual improvement over time, suggesting partial reversibility.
Cerebral Perfusion Imaging
Arterial spin labeling MRI and single-photon emission computed tomography (SPECT) permit assessment of regional cerebral blood flow.
Reported abnormalities include reduced perfusion involving:
- frontal lobes;
- temporal cortex;
- parietal association areas;
- cerebellum.
These findings support the hypothesis that impaired microvascular circulation contributes to persistent neurological symptoms.
Retinal Microvascular Imaging
The retinal circulation provides a unique window into cerebral microvascular health.
Optical coherence tomography angiography (OCTA) has demonstrated:
- reduced capillary density;
- altered retinal perfusion;
- enlarged foveal avascular zones.
Because retinal and cerebral vessels share embryological origins, retinal imaging may eventually provide a useful non-invasive biomarker of systemic microvascular dysfunction.
Clinical Presentation
Neurological manifestations vary enormously among patients.
Symptoms may fluctuate daily and frequently worsen after physical or cognitive exertion.
The most common neurological complaints include:
Cognitive Dysfunction
Patients commonly describe:
- “brain fog”;
- inability to concentrate;
- slowed thinking;
- impaired multitasking;
- forgetfulness;
- reduced vocabulary retrieval;
- difficulty following conversations;
- impaired decision-making.
Formal neuropsychological testing often demonstrates measurable impairment despite normal bedside neurological examination.
Executive Dysfunction
Executive function encompasses:
- planning;
- organization;
- prioritization;
- problem solving;
- mental flexibility;
- inhibition of inappropriate responses.
Many patients report inability to perform occupational responsibilities previously accomplished with ease.
Professionals including physicians, engineers, attorneys, pilots, educators, and executives have described dramatic declines in cognitive efficiency despite preserved intelligence.
Attention Deficits
Attention deficits may involve:
- sustained attention;
- divided attention;
- selective attention.
Patients often report:
“I can read an entire page and realize I remember nothing.”
Others describe losing track of conversations after only a few sentences.
These symptoms may significantly impair occupational performance.
Memory Impairment
Memory disturbances frequently involve:
Working Memory
Difficulty temporarily holding information.
Examples include:
- forgetting telephone numbers immediately;
- losing track of multi-step instructions;
- inability to mentally calculate.
Episodic Memory
Patients may forget:
- recent conversations;
- appointments;
- names;
- locations of personal belongings.
Prospective Memory
Difficulty remembering future intentions.
Examples include:
- forgetting medications;
- missing appointments;
- failing to complete planned tasks.
Language Dysfunction
Although aphasia is uncommon, subtle language impairment frequently occurs.
Patients report:
- word-finding difficulty;
- slowed verbal fluency;
- circumlocution;
- impaired reading comprehension.
These symptoms often fluctuate with fatigue.
Mental Fatigue
Mental fatigue differs fundamentally from ordinary tiredness.
Patients describe:
“My brain simply runs out of energy.”
Relatively minor cognitive activity may require prolonged recovery.
This phenomenon resembles post-exertional symptom exacerbation observed after physical activity.
Functional Impairment
Neurological symptoms often translate into substantial reductions in daily functioning.
Affected domains include:
- employment;
- financial management;
- driving;
- medication adherence;
- household management;
- academic performance;
- social interaction.
Some previously independent individuals become unable to maintain employment or perform instrumental activities of daily living.
Spectrum of Neurological Infirmity
The severity of neurological involvement spans a broad continuum.
Mild
- intermittent brain fog;
- occasional forgetfulness;
- mild headaches;
- preserved employment.
Moderate
- measurable neuropsychological impairment;
- reduced occupational performance;
- inability to multitask;
- exercise intolerance.
Severe
- inability to work;
- profound executive dysfunction;
- disabling fatigue;
- autonomic instability;
- dependence upon caregivers.
Relationship Between Acute Disease Severity and Long-Term Neurological Outcome
One of the most striking observations has been that persistent cognitive impairment may develop even after initially mild COVID-19.
While severe acute illness increases the risk of long-term neurological sequelae, persistent cognitive symptoms have also been reported following infections that never required hospitalization. This indicates that mechanisms beyond critical illness—such as endothelial dysfunction, immune dysregulation, autonomic abnormalities, and possibly microvascular changes—may contribute to Long COVID.
Diagnostic Evaluation, Biomarkers, Differential Diagnosis, Therapeutic Strategies, and Long-Term Outcomes
Diagnostic Evaluation
One of the greatest challenges facing clinicians is the absence of a universally accepted diagnostic test for cerebral microvascular dysfunction associated with Long COVID. Diagnosis remains primarily clinical, supported by objective evidence of cognitive impairment, autonomic dysfunction, vascular injury, and exclusion of competing neurological disorders.
A comprehensive diagnostic evaluation should integrate clinical history, neurological examination, laboratory testing, neuropsychological assessment, neuroimaging, and—where indicated—specialized autonomic or vascular studies. Given the heterogeneity of Long COVID, individualized assessment is essential.
Clinical History
A detailed history should document:
- timing and severity of acute SARS-CoV-2 infection;
- vaccination history;
- prior neurological disease;
- cerebrovascular risk factors;
- autoimmune disorders;
- medications;
- progression and fluctuation of symptoms;
- exertional intolerance;
- sleep quality;
- psychiatric symptoms;
- occupational impairment.
Patients frequently report a relapsing-remitting course, with symptom exacerbation following physical, cognitive, or emotional stress.
Neurological Examination
The neurological examination is often normal or only subtly abnormal despite significant subjective complaints. Findings may include:
- slowed cognitive processing;
- impaired attention;
- mild executive dysfunction;
- gait instability;
- sensory deficits (when concurrent peripheral neuropathy is present);
- orthostatic tachycardia or hypotension;
- impaired balance.
The relative paucity of focal neurological signs distinguishes many Long COVID presentations from acute stroke or demyelinating disorders.
Neuropsychological Assessment
Formal neuropsychological testing provides objective documentation of cognitive deficits and can guide rehabilitation.
Domains commonly evaluated include:
- attention;
- processing speed;
- working memory;
- verbal learning;
- visual memory;
- executive function;
- language;
- visuospatial skills.
Frequently used instruments include:
- Montreal Cognitive Assessment (MoCA);
- Trail Making Test Parts A and B;
- Digit Span;
- Symbol Digit Modalities Test;
- Stroop Color–Word Test;
- Rey Auditory Verbal Learning Test;
- Controlled Oral Word Association Test.
Many patients demonstrate impairments in processing speed and executive function despite preserved general intellectual ability.
Laboratory Biomarkers
No single biomarker is diagnostic for Long COVID or cerebral microvascular dysfunction. Laboratory evaluation is therefore directed toward identifying evidence of inflammation, coagulation abnormalities, endothelial injury, and alternative diagnoses.
Hematologic and Coagulation Markers
Common investigations include:
- complete blood count;
- D-dimer;
- fibrinogen;
- prothrombin time (PT);
- activated partial thromboplastin time (aPTT);
- platelet count.
Elevated D-dimer is common during acute COVID-19 but is less consistently abnormal in Long COVID. Persistent elevation, when present, warrants evaluation for ongoing thrombosis or alternative pathology.
Inflammatory Markers
Potential markers include:
- C-reactive protein (CRP);
- erythrocyte sedimentation rate (ESR);
- ferritin;
- interleukin-6 (IL-6) in research settings.
These markers are nonspecific and may be normal despite significant symptoms.
Endothelial Dysfunction
Research studies have investigated:
- von Willebrand factor;
- Factor VIII;
- soluble thrombomodulin;
- soluble ICAM-1;
- soluble VCAM-1.
Although promising as indicators of endothelial activation, these assays are not routinely used in clinical practice.
Microclot Detection
Specialized laboratories have developed fluorescence microscopy protocols using amyloid-binding dyes to identify fibrin-rich microclots in platelet-poor plasma. While these techniques have generated considerable scientific interest, they remain research tools. Standardization, external validation, and demonstration of clinical utility are still lacking, and they are not recommended as routine diagnostic tests at present.
Differential Diagnosis
The nonspecific nature of cognitive symptoms necessitates careful exclusion of other conditions.
Important differential diagnoses include:
- Alzheimer’s disease;
- vascular cognitive impairment;
- Parkinson disease;
- multiple sclerosis;
- autoimmune encephalitis;
- myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS);
- major depressive disorder;
- generalized anxiety disorder;
- sleep apnea;
- hypothyroidism;
- vitamin B12 deficiency;
- folate deficiency;
- neurosarcoidosis;
- systemic lupus erythematosus;
- medication-induced cognitive impairment.
Because several of these conditions may coexist with Long COVID, clinicians should avoid premature diagnostic closure.
Current Therapeutic Strategies
At present, no therapy has been conclusively shown in randomized controlled trials to eliminate cerebral microclots or reverse Long COVID neurological symptoms. Management is therefore multidisciplinary and focused on symptom reduction, rehabilitation, and treatment of identifiable comorbidities.
Anticoagulant Therapy
Hypercoagulability in acute COVID-19 is well established, and anticoagulation reduces thrombotic complications in selected hospitalized patients. Whether prolonged anticoagulation benefits patients with Long COVID and suspected microvascular dysfunction remains uncertain.
Small observational studies have explored combinations of direct oral anticoagulants and antiplatelet agents in carefully selected patients, but these studies have important methodological limitations, including small sample size, lack of randomization, and bleeding risk. Major professional societies do not currently recommend routine anticoagulation for Long COVID in the absence of another accepted indication.
Antiplatelet Therapy
Low-dose aspirin and P2Y12 inhibitors have also been proposed as potential therapies to reduce platelet activation. Evidence is limited, and treatment decisions should weigh uncertain benefit against the risk of gastrointestinal or intracranial bleeding, particularly in older adults or those with chronic kidney disease.
Fibrinolytic Strategies
Because some investigators have reported fibrin structures resistant to normal fibrinolysis, interest has arisen in therapies aimed at enhancing clot breakdown. At present, however, fibrinolytic drugs such as alteplase carry substantial hemorrhagic risk and should not be used outside approved indications or carefully designed clinical trials.
Immunomodulatory Therapies
Persistent immune activation has led to investigation of:
- corticosteroids;
- intravenous immunoglobulin (IVIG);
- low-dose naltrexone;
- Janus kinase (JAK) inhibitors;
- anti-cytokine therapies.
Evidence varies by intervention. IVIG may benefit selected patients with confirmed immune-mediated neuropathies, while low-dose naltrexone has shown preliminary promise in small observational studies for fatigue and pain but requires larger randomized trials.
Endothelial Protection
Strategies aimed at improving endothelial health include:
- aggressive management of hypertension;
- treatment of diabetes mellitus;
- lipid-lowering therapy when indicated;
- smoking cessation;
- regular physical activity as tolerated;
- Mediterranean-style dietary patterns.
Although not specific to Long COVID, these measures may improve overall vascular health and reduce the risk of future cerebrovascular events.
Cognitive Rehabilitation
Structured cognitive rehabilitation is increasingly recommended for patients with persistent cognitive deficits. Programs may include:
- memory training;
- attention exercises;
- executive function coaching;
- compensatory strategies;
- occupational therapy;
- speech-language pathology interventions.
Patients often benefit from pacing cognitive activity, using reminders and organizational tools, and gradually increasing cognitive demands.
Autonomic Rehabilitation
For patients with dysautonomia or postural orthostatic tachycardia syndrome (POTS), non-pharmacologic measures such as increased fluid and salt intake (when medically appropriate), compression garments, and supervised exercise programs emphasizing recumbent or semi-recumbent activity may reduce symptoms. Pharmacologic therapies should be individualized and guided by autonomic specialists.
Long-Term Outcomes
Long-term prognosis varies widely. Many individuals improve gradually over months, whereas others experience persistent symptoms extending for years. Factors associated with poorer outcomes include severe acute illness, pre-existing cardiovascular disease, diabetes, obesity, and older age, although significant disability has also been reported after mild infections.
Most longitudinal studies suggest that cognitive function improves in a substantial proportion of patients over time, but recovery may be incomplete. The mechanisms underlying persistent deficits remain uncertain and likely differ among individuals.
Future Directions
Key priorities for future research include:
- standardized definitions of Long COVID phenotypes;
- validated assays for endothelial dysfunction and microvascular injury;
- randomized controlled trials of antithrombotic and immunomodulatory therapies;
- biomarkers to identify patients most likely to benefit from targeted interventions;
- long-term cohort studies integrating neuroimaging, neuropsychological testing, and functional outcomes.
A better understanding of the relationship between microvascular pathology, immune dysregulation, and persistent neurological symptoms will be essential for developing effective treatments.
Conclusion
The neurological manifestations of Long COVID represent a complex interplay of vascular, immunological, metabolic, and neuroinflammatory processes. Cerebral microvascular dysfunction and fibrin-rich microclots are biologically plausible contributors to persistent cognitive impairment, but current evidence does not establish them as the sole or universal cause of “brain fog” or other neurological sequelae. Endothelial injury, blood–brain barrier disruption, platelet activation, mitochondrial dysfunction, autonomic abnormalities, and chronic immune activation likely interact to produce the diverse clinical phenotypes observed.
While advances in neuropathology, neuroimaging, and vascular biology have substantially expanded our understanding of these mechanisms, important uncertainties remain. Future well-designed clinical trials and longitudinal studies will be required to clarify causality, identify reliable biomarkers, and establish evidence-based therapies that improve long-term neurological outcomes for individuals affected by Long COVID.
References
- Lee MH, et al. Microvascular injury in the brains of patients with COVID-19. New England Journal of Medicine. 2021.
- Douaud G, et al. SARS-CoV-2 is associated with changes in brain structure in UK Biobank. Nature. 2022.
- Hosp JA, et al. Cognitive impairment and altered cerebral glucose metabolism in Long COVID. Brain. 2021.
- Meinhardt J, et al. Olfactory transmucosal SARS-CoV-2 invasion and CNS involvement. Nature Neuroscience. 2021.
- Matschke J, et al. Neuropathology of patients with COVID-19 in Germany. Lancet Neurology. 2020.
- Nalbandian A, et al. Post-acute COVID-19 syndrome. Nature M